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In a previous article [1], we expressed concern about methods of conduction of the most important 
studies, related to the most significant publications about HIV natural history and its management, 
which, since 2008, have been based on studies conducted on a consistent number of patients from all 
over the world, with the main aim to obtain, in relatively short time, statistical significant data (not 
always synonymous of statistical clinical meaning). Moreover, these mega-studies (often retrospective 
analyses, or post-hoc experiences) were signed by hundreds of the so called “collaborators”, all of them 
“elevated” to the rank of true Authors, through the placement of each single name in all major databa-
ses and search engines of the international scientific literature, right since 2008 [1].
In the following years (2009-2010) this phenomenon has, if possible, increased exponentially, leading 
to a multiplication of these “collaborators”, who, until that date, were just listed in a note in the Ack-
nowledgments section of the article, and were not considered as real authors. The current situation se-
ems to lead to a somewhat unacceptable inflation of the author’s role itself in biomedical publications, 
based on the well-known statement that should be considered as author one that has given a substantial 
supply to the design of the study, data results and evaluation, while those who contribute to data collec-
tion cannot be included among the Authors.
As a specialist in infective diseases, here I would like only to highlight the situation of the most relevant 
studies in HIV infection, but obviously the same “infection” is contaminating (to use a word common 
in my field) the whole world of biomedical literature. Even though it is necessary to have wide data-
bases aiming at evaluating the events that happen less frequently, to examine consistent long-term 
endpoints or pharmacologic safety profiles, nonetheless considerable bias and distortions happen, as 
a consequence of the extremely high number of the Centres and of the investigators, recruited in a 
planetary scale [1].
As an example, in Table I are listed the most significant and recent studies (published in 2009-2010) 
that have also affected the guidelines of the management of HIV-related comorbidities. These studies 
appear to be burdened by an enormous number of authors and collaborators that clashes especially if 
compared with the number of patients of cases followed, and with the times of observation and inter-
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vention. In these studies about HIV infection and AIDS, the so-called collaborators represent in reality 
the responsible of the Clinical Centres involved, all over the world, in the study, and in addition some 
sub-investigators of the belonging to the same Centres, who, in most of the cases, are responsible for 
the enrolling or the registration of a very little number of patients or events for each Centre or each 
investigator. For example, a trial published in 2010 has been signed by 13 principle authors and 80 
collaborators, all indexed on PubMed-Medline. These authors examined the pharmacokinetic charac-
teristics of an antiretroviral agent administered in association with another anti-HIV drug in no more 
than 54 patients, followed for 6 months [2]: it is therefore evident that each collaborator has followed 
an avarage of 0.58 patients, and nonetheless is included among the authors of a relevant scientific pu-
blication, included in PubMed with its update in 2008.
Likewise, a total of 204 authors and collaborators analysed the temporal suppression of HIV viraemia 
as a predictive factor of virologic failure in 451 patients (that is to say, an avarage of 2.21 patients enrol-
led by each collaborator or author) [3]. A previous trial, published in 2009, examined the role of inter-
leukin-2 in 5,806 patients followed for 7 years, but the total number of authors plus collaborators is 967 
(an avarage of 6 patients, thanks to which every collaborator has been listed as author of the prestigious 
New England Journal of Medicine) [4].
At the same time, all these mega-trials that have an extreme high power in affecting clinical practice, 
because their results are included in international clinical guidelines about HIV management, can lead 
to distortions, and in particular the possibility that a sort of hyperinflation of the number of the sam-
ples have been made in favour of statistic evaluations: a high number of patients or events or post-hoc 
analysis are usually made on data coming from hundreds of Centres disseminated all over the world, 
aiming at reaching a sufficient statistical power, without taking into consideration the possible bias 
regarding enrolling, measurement, and registration of extremely sensible data, of the time passed in 
long term studies, and of the inter-human differences about gender, race, BMI, and genetic and phar-
macogenomic features, only to cite some of the most evident examples [1].
Parallely, in the same studies there is, as previously described, the phenomenon of the inflation of the 
number of the so called co-authors (in reality, nothing more than collaborators), that introduces other di-
stortions during the evaluation of the scientific production of each investigator. Unavoidable consequen-
ces are then possible in the evaluation of academic curricula and in the consequent recognitions, for the 
obtainment of institutional funds, or external sponsorships, or the prestige of the institutions themselves.
In reality, the problem of the proliferation (sometimes inadequate) of the authorship is a well known 
phenomenon since twenty years and concerns all the fields of the research and clinical medicine, but 
nonetheless is and remains a scarcely debated topic, as emerged from the few articles published [5-9].
In my opinion, all the involved authorities, starting form scientific associations and biomedical journals 
and publishers, should become aware of this increasing problem and of the implicit distortion and 
scientific, technical, and ethical related consequences, with the goal of developing some rules that can 
guarantee the maintenance of the central and critical role of the authorship, as currently intended, and 
of preventing and avoiding the main bias related to the conduction of mega-trials and inter-cohort 
analyses, often signed by a disproportionate number of co-authors. Probably, it appears correct to list 
an adequate number of authors that contributed in first person in conceiving, following, writing and 
discussing the study (the so called “steering committee”). The remaining co-investigators should better 
be represented using an acronym or a “corporate” denomination, that comprehends in a single abbre-
viation all the co-investigators that took part in the study, that can be then listed in a specific appendix, 
or in the standard Acknowledgement section, as it happened before 2008 (and as reported in the recent 
HIV-Causal Collaboration study which, even if not listing any author, allowed the inclusion in PubMed 
of even 1.179 presumed “co-authors”) [10]. 
Scientific and practical consequences related to the publication and diffusion of these mega-trials de-
serve the maximum attention of all the scientific community.
Main outcome and main  
 endpoints of the study
Sample  
(n. pz.)
Study 
period
Main  
authors 
(n.)
“Co-authors” 
(fully indexed 
in PubMed - 
Medline) (n.)
Reference 
Mortality of HIV-related events 31,620 43 months 19 855 Clin Infect Dis 2009; 48: 1138
HIV infection therapy with interleukin-2 5,806 7-8 years 18 949 N Engl J Med 2009; 361: 1548
Efficacy and safety of etravirin 1,203 48 weeks 12 181 AIDS 2009; 23: 2289
Accumulation rate of viral mutation during 
NRTI therapy 
538 pt./
year
4.3 years 10 176 J Infect Dis 2009; 200: 687
Virologic outcome based on genotipic 
resistance that determines therapeutic 
variation
634 24 weeks 15 102 J Antimicrob Chemother 2009; 
64: 616
Viral interferences in HIV-positive patients co-
infected with HBV, and/or HDV, and/or HCV
72 N.D. 12 147 J AIDS 2009; 51: 574
Mortality rate for HIV-infection and 
tubercular co-infection
1,075 3 years 19 353 AIDS 2009; 23: 2485
Response to interferon-ribavirin therapy in 
patients HIV-HCV co-infected 
100 24-72 
weeks
11 41 Curr HIV Res 2009; 7: 447
Co-infection with HCV and CD4+ 
lymphocites count
4,208 < 3 years 10 148 J AIDS 2009; 50: 457
Interruption of nevirapine because of toxicity, 
or patient’s or physician’s choice 
16,733 N.D. 11 435 AIDS 2009; 23: 1689
Effects of the antiretroviral therapy on overall 
mortality 
62,760 3.3 years 0 1,179 AIDS 2010; 24: 123
Life-expectancy in case of HIV-infection of 
recent diagnosis 
17,580 
pt./year
6 months 5 130 AIDS 2010; 24: 1527
Definition of metabolic syndrome in HIV-
infected patients 
178,835 
pt./year
7 years 10 596 AIDS 2010; 24: 427
Mortality rate in patients naïve to 
antiretrovirals with CD4+ lymphocytes count 
> 350 cells/µl
80,682 
pt./year
N.D. 24 353 Lancet 2010; 376: 340
Duration of the HIV replicative suppression as 
predictor of virologic failure after therapeutic 
switch 
451 N.D. 10 194 HIV Med 2010; 11: 469
Increase of CD4+ lymphocites count during 
viremic suppression, in relation to previous 
virologic failure
3,537 Up to
51 months
15 118 Clin Infect Dis 2010; 51: 456
Incidence of malignant carcinoma and 
prognostic role of CD4+ lymphocytes count 
6,695 58 months 12 143 Clin Infect Dis 2010; 50: 1316
Renal toxicity in HIV-positive patients treated 
with antiretroviral drugs 
21,482 
pt./year
N.D. 10 197 AIDS 2010; 24: 1667
Plasmatic concentrations of raltegravir with 
and without administration of maraviroc
54 6 months 13 80 Ann Pharmacother 2010; 44: 
838
Tolerability of atazanavir-ritonavir versus 
lopinavir-ritonavir
599 6 months 7 105 AIDS Care 2010; 22: 677
Correlation between genotype and HBV 
viraemia during chronic hepatitis in HIV-
positive patients
16,505 N.D. 10 196 J Antimicrob Chemother 2010; 
65: 548
Table I. Highly relevant studies published in 2009-2010 about the natural history and management of 
HIV infection and related complications, listed highlighting the number of authors and co-authors, as 
cited in PubMed-Medline database
ND = transversal studies or investigations performed with follow-up times different for each group of patients 
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investigator. For example, a trial published in 2010 has been signed by 13 principle authors and 80 
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(an avarage of 6 patients, thanks to which every collaborator has been listed as author of the prestigious 
New England Journal of Medicine) [4].
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because their results are included in international clinical guidelines about HIV management, can lead 
to distortions, and in particular the possibility that a sort of hyperinflation of the number of the sam-
ples have been made in favour of statistic evaluations: a high number of patients or events or post-hoc 
analysis are usually made on data coming from hundreds of Centres disseminated all over the world, 
aiming at reaching a sufficient statistical power, without taking into consideration the possible bias 
regarding enrolling, measurement, and registration of extremely sensible data, of the time passed in 
long term studies, and of the inter-human differences about gender, race, BMI, and genetic and phar-
macogenomic features, only to cite some of the most evident examples [1].
Parallely, in the same studies there is, as previously described, the phenomenon of the inflation of the 
number of the so called co-authors (in reality, nothing more than collaborators), that introduces other di-
stortions during the evaluation of the scientific production of each investigator. Unavoidable consequen-
ces are then possible in the evaluation of academic curricula and in the consequent recognitions, for the 
obtainment of institutional funds, or external sponsorships, or the prestige of the institutions themselves.
In reality, the problem of the proliferation (sometimes inadequate) of the authorship is a well known 
phenomenon since twenty years and concerns all the fields of the research and clinical medicine, but 
nonetheless is and remains a scarcely debated topic, as emerged from the few articles published [5-9].
In my opinion, all the involved authorities, starting form scientific associations and biomedical journals 
and publishers, should become aware of this increasing problem and of the implicit distortion and 
scientific, technical, and ethical related consequences, with the goal of developing some rules that can 
guarantee the maintenance of the central and critical role of the authorship, as currently intended, and 
of preventing and avoiding the main bias related to the conduction of mega-trials and inter-cohort 
analyses, often signed by a disproportionate number of co-authors. Probably, it appears correct to list 
an adequate number of authors that contributed in first person in conceiving, following, writing and 
discussing the study (the so called “steering committee”). The remaining co-investigators should better 
be represented using an acronym or a “corporate” denomination, that comprehends in a single abbre-
viation all the co-investigators that took part in the study, that can be then listed in a specific appendix, 
or in the standard Acknowledgement section, as it happened before 2008 (and as reported in the recent 
HIV-Causal Collaboration study which, even if not listing any author, allowed the inclusion in PubMed 
of even 1.179 presumed “co-authors”) [10]. 
Scientific and practical consequences related to the publication and diffusion of these mega-trials de-
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